Stocks and Investing Stocks and Investing
Wed, April 26, 2023

Carter Gould Maintained (BIIB) at Hold with Decreased Target to $302 on, Apr 26th, 2023


Published on 2024-10-28 03:03:02 - WOPRAI, Carter Gould
  Print publication without navigation


Carter Gould of Barclays, Maintained "Biogen Inc." (BIIB) at Hold with Decreased Target from $307 to $302 on, Apr 26th, 2023.

Carter has made no other calls on BIIB in the last 4 months.



There are 6 other peers that have a rating on BIIB. Out of the 6 peers that are also analyzing BIIB, 1 agrees with Carter's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Geoff Meacham of "B of A Securities" Maintained at Hold with Increased Target to $300 on, Friday, April 21st, 2023


These are the ratings of the 5 analyists that currently disagree with Carter


  • Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Increased Target to $320 on, Monday, April 17th, 2023
  • Christopher Raymond of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $346 on, Monday, April 17th, 2023
  • Matthew Korn of "Morgan Stanley" Maintained at Buy with Decreased Target to $349 on, Wednesday, April 12th, 2023
  • Phil Nadeau of "Cowen & Co." Maintained at Buy with Increased Target to $315 on, Thursday, February 16th, 2023
  • Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $340 on, Thursday, February 16th, 2023
Contributing Sources